Epigenetic changes in colorectal cancer

Chinese Journal of Cancer

Volumn 32, Issue 1, 2013, Pages 21-30

  Jia, Yan ^a,b   Guo, Mingzhou ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NANKAI UNIVERSITY   (China)

Author keywords

Colorectal cancer (CRC); DNA methylation; Epigenetics; Field defect; Histone modification; MicroRNA (miRNA)

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA; FOLIC ACID; HISTONE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; MICRORNA; TRICHOSTATIN A; VORINOSTAT;

CANCER CLASSIFICATION; COLON CARCINOGENESIS; COLORECTAL CANCER; CPG ISLAND; DIET; DNA METHYLATION; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; EPIGENETICS; FOLIC ACID DEFICIENCY; HISTONE MODIFICATION; HUMAN; LIFESTYLE; PHENOTYPE; PROMOTER REGION; REVIEW;

COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FOLIC ACID DEFICIENCY; GENOMIC IMPRINTING; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; MICRORNAS; PROMOTER REGIONS, GENETIC; RNA, UNTRANSLATED;

EID: 84872191135     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10245     Document Type: Review

References (130)

1. Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet, 2007, 370: 2020-2029.
2. Arnold CN, Goel A, Blum HE, et al. Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer, 2005,104:2035-2047.
3. Grady WM, Carethers JM. Genomic and epigenetic instability incolorectal cancer pathogenesis. Gastroenterology, 2008,135: 1079-1099.
4. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med, 2009,361: 2449-2460.
5. Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature, 2004,429:457-463.
6. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood, 2004,103:1635-1640.
7. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science, 2001,293:1068-1070.
8. Csankovszki G, Nagy A, Jaenisch R. Synergism of Xist RNA, DNA methylation, and histone hypoacetylation in maintaining X chromosome inactivation. J Cell Biol, 2001,153:773-784.
9. Bird AP. CpG-rich islands and the function of DNA methylation. Nature, 1986,321:209-213.
10. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev, 2002,16:6-21.
11. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer, 2003,3:253-266.
12. Jair KW, Bachman KE, Suzuki H, et al. De novo CpG island methylation in human cancer cells. Cancer Res, 2006,66:682-692.
13. Copeland RA, Olhava EJ, Scott MP. Targeting epigenetic enzymes for drug discovery. Curr Opin Chem Biol, 2010,14: 505-510.
14. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer, 2001,1: 194-202.
15. Kaneda M, Okano M, Hata K, et al. Essential role for de novo NA methyltransferase Dnmt3a in paternal and maternal imprinting. Nature, 2004,429:900-903.
16. Chen ZX, Mann JR, Hsieh CL, et al. Physical and functional nteractions between the human Dnmt3l protein and members of the de novo methyltransferase family. J Cell Biochem, 2005,95:902-917.
17. Dong A, Yoder JA, Zhang X, et al. Structure of human dnmt2, an enigmatic DNA methyltransferase homolog that displays denaturant-re sistant binding to DNA. Nucleic Acids Res, 2001,29:439-448.
18. Free A, Wakefield RI, Smith BO, et al. DNA recognition by the ethyl-C pG binding domain of MeCP2. J Biol Chem, 2001,276:3353-3360.
19. Meehan RR, Lewis JD, Bird AP. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res, 1992,20:5085-5092.
20. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer, 2006,6:846-856.
21. Mai A. The therapeutic uses of chromatin-m odifying agents. Expert Opin Ther Targets, 2007,11:835-851.
22. Esteller M, Fraga MF, Guo M, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet, 2001,10:3001-3007.
23. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res, 2001,61:3225-3229.
24. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A, 1999,96:8681-8686.
25. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst, 2005,97:1330-1338.
26. Kawakami K, Ruszkiewicz A, Bennett G, et al. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer, 2006,94:593-598.
27. Menigatti M, Truninger K, Gebbers JO, et al. Normal colorectal mucosa exhibits sex- and segment-s pecific susceptibility to DNA methylation at the hMIH1 and MGMT promoters. Oncogene, 2009,28:899-909.
28. Esteller M. Epigenetics in cancer. N Engl J Med, 2008,358: 1148-1159.
29. Ahuja N, Li Q, Mohan AL, et al. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res, 1998,58:5489-5494.
30. Riojas MA, Guo M, Glockner SC, et al. Methylation-in duced silencing of ASC/TMS1, a pro-apoptotic gene, is a late-s tage event in colorectal cancer. Cancer Biol Ther, 2007,6:1710-1716.
31. Zhang W, Glockner SC, Guo M, et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res, 2008,68:2764-2772.
32. Lee BB, Lee EJ, Jung EH, et al. Aberrant methylation of APC, MGMT, RASSF2A, and WIf-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res, 2009,15:6185-6191.
33. Grady WM, Rajput A, Lutterbaugh JD, et al. Detection of aberrantly methylated hMIH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res, 2001,61:900-902.
34. Zou HZ, Yu BM, Wang ZW, et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin Cancer Res, 2002,8:188-191.
35. Nakayama H, Hibi K, Taguchi M, et al. Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients. Cancer Lett, 2002,188:115-119.
36. Yamaguchi S, Asao T, Nakamura J, et al. High frequency of DAP-k inase gene promoter methylation in colorectal cancer specimens and its identification in serum. Cancer Lett, 2003,194:99-105.
37. Fearon ER, Vogelstein B. A genetic model for colorectal umorigenesis. Cell, 1990,61:759-767.
38. Kambara T, Simms LA, Whitehall VL, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut, 2004,53:1137-1144.
39. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology, 2010,138:2073-2087.
40. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer, 2004,4:988-993.
41. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev, 2010, 29: 181-206.
42. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature, 1983,301:89-92.
43. Hibi K, Goto T, Mizukami H, et al. Demethylation of the CDH3 gene is frequently detected in advanced colorectal cancer. Anticancer Res, 2009,29:2215-2217.
44. Braakhuis BJ, Tabor MP, Kummer JA, et al. A genetic explanation of slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res, 2003,63:1727-1730.
45. Guo M, House MG, Hooker C, et al. Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res, 2004,10:5131-5136.
46. Rainier S, Johnson LA, Dobry CJ, et al. Relaxation of imprinted genes in human cancer. Nature, 1993,362:747-749.
47. Ogawa O, Eccles MR, Szeto J, et al. Relaxation of insulin-lik e growth factor II gene imprinting implicated in Wilms' tumour. Nature, 1993,362:749-751.
48. Cui H, Horon IL, Ohlsson R, et al. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med, 1998,4:1276-1280.
49. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer, 2004,4:143-153.
50. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science, 2003,299:1753-1755.
51. McMichael AJ. Food, nutrition, physical activity and cancer prevention. Authoritative report from World Cancer Research Fund provides global update. Public Health Nutr, 2008,11:762-763.
52. Shaw S, Jayatilleke E, Herbert V, et al. Cleavage of folates during ethanol metabolism. Role of acetaldehyde/xanthine oxidase-generated superoxide. Biochem J, 1989, 257: 277-280.
53. Romero JJ, Tamura T, Halsted CH. Intestinal absorption of [3H] folic acid in the chronic alcoholic monkey. Gastroenterology, 1981,80:99-102.
54. Eichner ER, Hillman RS. The evolution of anemia in alcoholic patients. Am J Med, 1971,50:218-232.
55. Pedersen A, Johansen C, Gronbaek M. Relations between amount and type of alcohol and colon and rectal cancer in a danish population based cohort study. Gut, 2003,52: 861-867.
56. Stemmermann GN, Nomura AM, Chyou PH, et al. Prospective study of alcohol intake and large bowel cancer. Dig Dis Sci, 1990,35:1414-1420.
57. Kim YI. Folate and colorectal cancer: an evidence-based critical review. Mol Nutr Food Res, 2007,51:267-292.
58. Sanjoaquin MA, Allen N, Couto E, et al. Folate intake and colorectal cancer risk: a meta-analytical approach. Int J Cancer, 2005,113:825-828.
59. James SJ, Pogribny IP, Pogribna M, et al. Mechanisms of DNA damage, DNA hypomethylation, and tumor progression in the folate/methyl-deficient rat model of hepatocarcinogenesis. J Nutr, 2003,133:3740S-3747S.
60. Berger SL. Histone modifications in transcriptional regulation. Curr Opin Genet Dev, 2002,12:142-148.
61. Barski A, Cuddapah S, Cui K, et al. High-re solution profiling of histone methylations in the human genome. Cell, 2007,129: 823-837.
62. Litt MD, Simpson M, Gaszner M, et al. Correlation between histone lysine methylation and developmental changes at the chicken beta- globin locus. Science, 2001,293:2453-2455.
63. Noma K, Allis CD, Grewal SI. Transitions in distinct histone H3 methylation patterns at the heterochromatin domain boundaries. Science, 2001,293:1150-1155.
64. Peters AH, Mermoud JE, O'Carroll D, et al. Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin. Nat Genet, 2002,30:77-80.
65. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet, 2005,37:391-400.
66. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature, 2005,435:1262-1266.
67. Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A, 2000,97:10014-10019.
68. Pruitt K, Zinn RL, Ohm JE, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet, 2006,2:e40.
69. Tsang DPF, Cheng ASL. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J Gastroenterol Hepatol, 2011,26:19-27.
70. Pelaez IM, Kalogeropoulou M, Ferraro A, et al. Oncogenic ras alters the global and gene-s pecific histone modification pattern during epithelial-m esenchymal transition in colorectal carcinoma cells. Int J Biochem Cell Biol, 2010,42:911-920.
71. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet, 2000,16(4):168-174.
72. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet, 1999,21:163-167.
73. Jenuwein T, Allis CD. Translating the histone code. Science, 2001,293:1074-1080.
74. Tamaru H, Selker EU. A histone H3 methyltransferase controls DNA methylation in neurospora crassa. Nature, 2001,414:277-283.
75. Jackson JP, Lindroth AM, Cao X, et al. Control of cpnpg DNA methylation by the kryptonite histone H3 methyltransferase. Nature, 2002,416:556-560.
76. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of HMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A, 1998,95: 6870-6875.
77. Fahrner JA, Eguchi S, Herman JG, et al. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res, 2002, 62: 7213-7218.
78. Wilson AJ, Byun DS, Popova N, et al. Histone deacetylase 3 (HDAC3) and other class I HDACS regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem, 2006,281:13548-13558.
79. Ishihama K, Yamakawa M, Semba S, et al. Expression of DAC1 and CBP/p300 in human colorectal carcinomas. J Clin Pathol, 2007,60:1205-1210.
80. Zhu P, Martin E, Mengwasser J, et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell, 2004,5:455-463.
81. Brehm A, Miska EA, McCance DJ, et al. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature, 1998,391:597-601.
82. Magnaghi-Jaulin L, Groisman R, Naguibneva I, et al. etinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature, 1998,391:601-605.
83. DePinho RA. Transcriptional repression. The cancer-chromatin connection. Nature, 1998,391:533, 535-536.
84. Kim YS, Tsao D, Siddiqui B, et al. Effects of sodium butyrate and dimethylsulfoxide on biochemical properties of human colon cancer cells. Cancer, 1980,45:1185-1192.
85. Dashwood RH, Ho E. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol, 2007,17:363-369.
86. Yoshida M, Kijima M, Akita M, et al. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin a. J Biol Chem, 1990, 265: 17174-17179.
87. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A, 1998,95: 3003-3007.
88. Myzak MC, Ho E, Dashwood RH. Dietary agents as histone deacetylase inhibitors. Mol Carcinog, 2006,45:443-446.
89. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs, 2007,16:659-678.
90. Mack GS. Epigenetic cancer therapy makes headway. J Natl ancer Inst, 2006,98:1443-1444.
91. Muller CI, Ruter B, Koeffler HP, et al. DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML. Curr Pharm Biotechnol, 2006,7:315-321.
92. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature, 2003,425:415-419.
93. Lund E, Guttinger S, Calado A, et al. Nuclear export of microrna precursors. Science, 2004,303:95-98.
94. Nilsen TW. Mechanisms of microRNA-m ediated gene regulation in animal cells. Trends Genet, 2007,23:243-249.
95. Wiemer EA. The role of microRNAs in cancer: no small matter. Eur J Cancer, 2007,43:1529-1544.
96. Michael MZ, SM OC, van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res, 2003,1:882-891.
97. Kitade Y, Akao Y. MicroRNAs and their therapeutic potential for human diseases: microRNAs, miR-143 and -145, function as anti-oncomirs and the application of chemically modified miR- 143 as an anti-cancer drug. J Pharmacol Sci, 2010,114:276-280.
98. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut, 2009,58: 1375-1381.
99. Koga Y, Yasunaga M, Takahashi A, et al. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res (Phila), 2010,3: 1435-1442.
100. Lagos-Quintana M, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed RNAs. Science, 2001,294:853-858.
101. Wang CJ, Zhou ZG, Wang L, et al. Clinicopathological significance of microRNA-31, -143 and-145 expression in colorectal cancer. Dis Markers, 2009,26:27-34.
102. Slaby O, Svoboda M, Fabian P, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology, 2007,72:397-402.
103. Wang CJ, Stratmann J, Zhou ZG, et al. Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells. BMC Cancer, 2010,10:616.
104. Cheng H, Zhang L, Cogdell DE, et al. Circulating plasma miR- 141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One, 2011,6:e17745.
105. Schepeler T, Reinert JT, Ostenfeld MS, et al. Diagnostic and prognostic micrornas in stage II colon cancer. Cancer Res, 2008,68:6416-6424.
106. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA, 2008,299:425-436.
107. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A, 2006,103:2257-2261.
108. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer, 2003,3:330-338.
109. Schetter AJ, Nguyen GH, Bowman ED, et al. Association of inflammation-re lated and microRNA gene expression with cancer-s pecific mortality of colon adenocarcinoma. Clin Cancer Res, 2009,15:5878-5887.
110. Bandres E, Agirre X, Bitarte N, et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer, 2009,125:2737-2743.
111. Balaguer F, Link A, Lozano JJ, et al. Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res, 2010,70:6609-6618.
112. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-1 27 with downregulation of the proto-oncogene BCL6 by chromatin-m odifying drugs in human cancer cells. Cancer Cell, 2006,9:435-443.
113. Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microrna in human cancer cells. Cancer Res, 2007,67:1424-1429.
114. Wang Z, Yuan X, Jiao N, et al. CDH13 and FIBN3 gene methylation are associated with poor prognosis in colorectal cancer. Pathol Oncol Res, 2012,18:263-270.
115. Mitomi H, Fukui N, Tanaka N, et al. Aberrant p16 ((INK4a)) methylation is a frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity. J Cancer Res Clin Oncol, 2010, 136:323-331.
116. Pancione M, Sabatino L, Fucci A, et al. Epigenetic silencing of peroxisome proliferator-activated receptor gamma is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS One, 2010,5:e14229.
117. Herath NI, Doecke J, Spanevello MD, et al. Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival. Br J Cancer, 2009,100:1095-1102.
118. Rawson JB, Manno M, Mrkonjic M, et al. Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patients. Carcinogenesis, 2011,32:741-747.
119. Kim JC, Lee HC, Cho DH, et al. Genome-wide identification of possible methylation markers chemosensitive to targeted regimens in colorectal cancers. J Cancer Res Clin Oncol, 2011,137:1571-1580.
120. Harder J, Engelstaedter V, Usadel H, et al. CpG-is land methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients. Br J Cancer, 2009,100:360-365.
121. Brandes JC, van Engeland M, Wouters KA, et al. CHFR promoter hypermethylation in colon cancer correlates with the icrosatellite instability phenotype. Carcinogenesis, 2005,26: 1152-1156.
122. Kim MS, Louwagie J, Carvalho B, et al. Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer. PLoS One, 2009,4: e6555.
123. Huang Z, Li L, Wang J. Hypermethylation of SFRP2 as a potential marker for stool-b ased detection of colorectal cancer and precancerous lesions. Dig Dis Sci, 2007,52:2287-2291.
124. Oberwalder M, Zitt M, Wontner C, et al. SFRP2 methylation in fecal DNA-a marker for colorectal polyps. Int J Colorectal Dis, 2008,23:15-19.
125. Mittag F, Kuester D, Vieth M, et al. DAPK promotor methylation is an early event in colorectal carcinogenesis. Cancer Lett, 2006,240:69-75.
126. Glockner SC, Dhir M, Yi JM, et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res, 2009,69:4691-4699.
127. Hellebrekers DM, Lentjes MH, van den Bosch SM, et al. GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res, 2009,15: 3990-3997.
128. Liu M, Peng Y, Wang X, et al. NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer. BMC Cancer, 2010,10:160.
129. Miotto E, Sabbioni S, Veronese A, et al. Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. Cancer Res, 2004,64:8156-8159.
130. Ishiguro A, Takahata T, Saito M, et al. Influence of methylated p15 and p16 genes on clinicopathological features in colorectal cancer. J Gastroenterol Hepatol, 2006,21:1334-1339.